

# W Fraser Symmans

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3126173/publications.pdf>

Version: 2024-02-01

158  
papers

23,051  
citations

13865

67  
h-index

8396

147  
g-index

165  
all docs

165  
docs citations

165  
times ranked

21420  
citing authors

#	ARTICLE	IF	CITATIONS
1	Response to Neoadjuvant Therapy and Long-Term Survival in Patients With Triple-Negative Breast Cancer. <i>Journal of Clinical Oncology</i> , 2008, 26, 1275-1281.	1.6	2,387
2	Breast Cancer Molecular Subtypes Respond Differently to Preoperative Chemotherapy. <i>Clinical Cancer Research</i> , 2005, 11, 5678-5685.	7.0	1,618
3	Measurement of Residual Breast Cancer Burden to Predict Survival After Neoadjuvant Chemotherapy. <i>Journal of Clinical Oncology</i> , 2007, 25, 4414-4422.	1.6	1,243
4	Sentinel Lymph Node Surgery After Neoadjuvant Chemotherapy in Patients With Node-Positive Breast Cancer. <i>JAMA - Journal of the American Medical Association</i> , 2013, 310, 1455.	7.4	1,153
5	The MicroArray Quality Control (MAQC)-II study of common practices for the development and validation of microarray-based predictive models. <i>Nature Biotechnology</i> , 2010, 28, 827-838.	17.5	795
6	Pharmacogenomic Predictor of Sensitivity to Preoperative Chemotherapy With Paclitaxel and Fluorouracil, Doxorubicin, and Cyclophosphamide in Breast Cancer. <i>Journal of Clinical Oncology</i> , 2006, 24, 4236-4244.	1.6	621
7	Differential Response to Neoadjuvant Chemotherapy Among 7 Triple-Negative Breast Cancer Molecular Subtypes. <i>Clinical Cancer Research</i> , 2013, 19, 5533-5540.	7.0	597
8	Gene Expression Profiles in Paraffin-Embedded Core Biopsy Tissue Predict Response to Chemotherapy in Women With Locally Advanced Breast Cancer. <i>Journal of Clinical Oncology</i> , 2005, 23, 7265-7277.	1.6	531
9	A Genomic Predictor of Response and Survival Following Taxane-Anthracycline Chemotherapy for Invasive Breast Cancer. <i>JAMA - Journal of the American Medical Association</i> , 2011, 305, 1873.	7.4	531
10	Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial. <i>Lancet Oncology</i> , The, 2018, 19, 497-509.	10.7	530
11	Metformin Promotes Antitumor Immunity via Endoplasmic-Reticulum-Associated Degradation of PD-L1. <i>Molecular Cell</i> , 2018, 71, 606-620.e7.	9.7	491
12	Long-Term Prognostic Risk After Neoadjuvant Chemotherapy Associated With Residual Cancer Burden and Breast Cancer Subtype. <i>Journal of Clinical Oncology</i> , 2017, 35, 1049-1060.	1.6	478
13	Adaptive Randomization of Veliparib+Carboplatin Treatment in Breast Cancer. <i>New England Journal of Medicine</i> , 2016, 375, 23-34.	27.0	467
14	Effect of Pembrolizumab Plus Neoadjuvant Chemotherapy on Pathologic Complete Response in Women With Early-Stage Breast Cancer. <i>JAMA Oncology</i> , 2020, 6, 676.	7.1	419
15	Neoadjuvant Chemotherapy, Endocrine Therapy, and Targeted Therapy for Breast Cancer: ASCO Guideline. <i>Journal of Clinical Oncology</i> , 2021, 39, 1485-1505.	1.6	395
16	Weekly Paclitaxel Improves Pathologic Complete Remission in Operable Breast Cancer When Compared With Paclitaxel Once Every 3 Weeks. <i>Journal of Clinical Oncology</i> , 2005, 23, 5983-5992.	1.6	383
17	Microtubule-associated protein tau: A marker of paclitaxel sensitivity in breast cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2005, 102, 8315-8320.	7.1	368
18	Preoperative Therapy in Invasive Breast Cancer: Pathologic Assessment and Systemic Therapy Issues in Operable Disease. <i>Journal of Clinical Oncology</i> , 2008, 26, 814-819.	1.6	352

#	ARTICLE	IF	CITATIONS
19	Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomised, open-label, multicentre, phase 3 trial. <i>Lancet Oncology</i> , The, 2018, 19, 115-126.	10.7	333
20	<i>PIK3CA</i> mutations associated with gene signature of low mTORC1 signaling and better outcomes in estrogen receptor-positive breast cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2010, 107, 10208-10213.	7.1	324
21	Adaptive Randomization of Neratinib in Early Breast Cancer. <i>New England Journal of Medicine</i> , 2016, 375, 11-22.	27.0	301
22	Molecular Characterization of Breast Cancer with High-Resolution Oligonucleotide Comparative Genomic Hybridization Array. <i>Clinical Cancer Research</i> , 2009, 15, 441-451.	7.0	300
23	Nomograms to Predict Pathologic Complete Response and Metastasis-Free Survival After Preoperative Chemotherapy for Breast Cancer. <i>Journal of Clinical Oncology</i> , 2005, 23, 8331-8339.	1.6	266
24	Residual Ductal Carcinoma In Situ in Patients With Complete Eradication of Invasive Breast Cancer After Neoadjuvant Chemotherapy Does Not Adversely Affect Patient Outcome. <i>Journal of Clinical Oncology</i> , 2007, 25, 2650-2655.	1.6	253
25	Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for <i>CYP2D6</i> and Tamoxifen Therapy. <i>Clinical Pharmacology and Therapeutics</i> , 2018, 103, 770-777.	4.7	244
26	Commercialized Multigene Predictors of Clinical Outcome for Breast Cancer. <i>Oncologist</i> , 2008, 13, 477-493.	3.7	235
27	Genomic Index of Sensitivity to Endocrine Therapy for Breast Cancer. <i>Journal of Clinical Oncology</i> , 2010, 28, 4111-4119.	1.6	235
28	Estrogen Receptor (ER) mRNA and ER-Related Gene Expression in Breast Cancers That Are 1% to 10% ER-Positive by Immunohistochemistry. <i>Journal of Clinical Oncology</i> , 2012, 30, 729-734.	1.6	231
29	Standardization of pathologic evaluation and reporting of postneoadjuvant specimens in clinical trials of breast cancer: recommendations from an international working group. <i>Modern Pathology</i> , 2015, 28, 1185-1201.	5.5	205
30	Molecular Anatomy of Breast Cancer Stroma and Its Prognostic Value in Estrogen Receptor-Positive and -Negative Cancers. <i>Journal of Clinical Oncology</i> , 2010, 28, 4316-4323.	1.6	193
31	Resistance to neoadjuvant chemotherapy in triple-negative breast cancer mediated by a reversible drug-tolerant state. <i>Science Translational Medicine</i> , 2019, 11, .	12.4	192
32	Evaluation of a 30-Gene Paclitaxel, Fluorouracil, Doxorubicin, and Cyclophosphamide Chemotherapy Response Predictor in a Multicenter Randomized Trial in Breast Cancer. <i>Clinical Cancer Research</i> , 2010, 16, 5351-5361.	7.0	185
33	Determination of oestrogen-receptor status and ERBB2 status of breast carcinoma: a gene-expression profiling study. <i>Lancet Oncology</i> , The, 2007, 8, 203-211.	10.7	175
34	Genomic Grade Index Is Associated With Response to Chemotherapy in Patients With Breast Cancer. <i>Journal of Clinical Oncology</i> , 2009, 27, 3185-3191.	1.6	173
35	Total RNA yield and microarray gene expression profiles from fine-needle aspiration biopsy and core-needle biopsy samples of breast carcinoma. <i>Cancer</i> , 2003, 97, 2960-2971.	4.1	170
36	Effect of training-sample size and classification difficulty on the accuracy of genomic predictors. <i>Breast Cancer Research</i> , 2010, 12, R5.	5.0	169

#	ARTICLE	IF	CITATIONS
37	Neoadjuvant Trastuzumab Emtansine and Pertuzumab in Human Epidermal Growth Factor Receptor 2â€“Positive Breast Cancer: Three-Year Outcomes From the Phase III KRISTINE Study. <i>Journal of Clinical Oncology</i> , 2019, 37, 2206-2216.	1.6	152
38	Gene expression profiles obtained from fine-needle aspirations of breast cancer reliably identify routine prognostic markers and reveal large-scale molecular differences between estrogen-negative and estrogen-positive tumors. <i>Clinical Cancer Research</i> , 2003, 9, 2406-15.	7.0	152
39	Residual cancer burden after neoadjuvant chemotherapy and long-term survival outcomes in breast cancer: a multicentre pooled analysis of 5161 patients. <i>Lancet Oncology</i> , The, 2022, 23, 149-160.	10.7	148
40	Identification of Prognosis-Relevant Subgroups in Patients with Chemoresistant Triple-Negative Breast Cancer. <i>Clinical Cancer Research</i> , 2013, 19, 2723-2733.	7.0	146
41	Change in tumor cellularity of breast carcinoma after neoadjuvant chemotherapy as a variable in the pathologic assessment of response. <i>Cancer</i> , 2004, 100, 1365-1373.	4.1	143
42	The path to a better biomarker: application of a risk management framework for the implementation of PDâ€“L1 and TILs as immunoâ€“oncology biomarkers in breast cancer clinical trials and daily practice. <i>Journal of Pathology</i> , 2020, 250, 667-684.	4.5	142
43	Durvalumab with olaparib and paclitaxel for high-risk HER2-negative stage II/III breast cancer: Results from the adaptively randomized I-SPY2 trial. <i>Cancer Cell</i> , 2021, 39, 989-998.e5.	16.8	131
44	Predictors of Tumor Progression During Neoadjuvant Chemotherapy in Breast Cancer. <i>Journal of Clinical Oncology</i> , 2010, 28, 1821-1828.	1.6	128
45	Association of Event-Free and Distant Recurrenceâ€“Free Survival With Individual-Level Pathologic Complete Response in Neoadjuvant Treatment of Stages 2 and 3 Breast Cancer. <i>JAMA Oncology</i> , 2020, 6, 1355.	7.1	119
46	Assessment of an RNA interference screen-derived mitotic and ceramide pathway metagene as a predictor of response to neoadjuvant paclitaxel for primary triple-negative breast cancer: a retrospective analysis of five clinical trials. <i>Lancet Oncology</i> , The, 2010, 11, 358-365.	10.7	116
47	The tale of TILs in breast cancer: A report from The International Immuno-Oncology Biomarker Working Group. <i>Npj Breast Cancer</i> , 2021, 7, 150.	5.2	112
48	Scoring of tumor-infiltrating lymphocytes: From visual estimation to machine learning. <i>Seminars in Cancer Biology</i> , 2018, 52, 151-157.	9.6	108
49	Mutation profiling identifies numerous rare drug targets and distinct mutation patterns in different clinical subtypes of breast cancers. <i>Breast Cancer Research and Treatment</i> , 2012, 134, 333-343.	2.5	106
50	Pitfalls in assessing stromal tumor infiltrating lymphocytes (sTILs) in breast cancer. <i>Npj Breast Cancer</i> , 2020, 6, 17.	5.2	106
51	Effects of Tissue Handling on RNA Integrity and Microarray Measurements From Resected Breast Cancers. <i>Journal of the National Cancer Institute</i> , 2011, 103, 1871-1883.	6.3	104
52	Ten-Year Outcomes of Patients With Breast Cancer With Cytologically Confirmed Axillary Lymph Node Metastases and Pathologic Complete Response After Primary Systemic Chemotherapy. <i>JAMA Oncology</i> , 2016, 2, 508.	7.1	103
53	Mammotome core biopsy for mammary microcalcification. <i>Cancer</i> , 2001, 91, 173-177.	4.1	98
54	Centromere protein-A, an essential centromere protein, is a prognostic marker for relapse in estrogen receptor-positive breast cancer. <i>Breast Cancer Research</i> , 2012, 14, R72.	5.0	96

#	ARTICLE	IF	CITATIONS
55	The Neo-Bioscore Update for Staging Breast Cancer Treated With Neoadjuvant Chemotherapy. <i>JAMA Oncology</i> , 2016, 2, 929.	7.1	94
56	Redefining breast cancer subtypes to guide treatment prioritization and maximize response: Predictive biomarkers across 10 cancer therapies. <i>Cancer Cell</i> , 2022, 40, 609-623.e6.	16.8	92
57	High-resolution clonal mapping of multi-organ metastasis in triple negative breast cancer. <i>Nature Communications</i> , 2018, 9, 5079.	12.8	91
58	Estrogen receptor (ER) mRNA expression and molecular subtype distribution in ER-negative/progesterone receptor-positive breast cancers. <i>Breast Cancer Research and Treatment</i> , 2014, 143, 403-409.	2.5	90
59	Report on computational assessment of Tumor Infiltrating Lymphocytes from the International Immuno-Oncology Biomarker Working Group. <i>Npj Breast Cancer</i> , 2020, 6, 16.	5.2	90
60	Higher parity and shorter breastfeeding duration. <i>Cancer</i> , 2010, 116, 4933-4943.	4.1	88
61	Effects of Obesity on Transcriptomic Changes and Cancer Hallmarks in Estrogen Receptor-Positive Breast Cancer. <i>Journal of the National Cancer Institute</i> , 2014, 106, .	6.3	87
62	Fine-needle aspiration cytology of Hodgkin disease. <i>Cancer</i> , 2001, 93, 52-59.	4.1	86
63	HER2 expression and efficacy of preoperative paclitaxel/FAC chemotherapy in breast cancer. <i>Breast Cancer Research and Treatment</i> , 2008, 108, 183-190.	2.5	85
64	Functional proteomics can define prognosis and predict pathologic complete response in patients with breast cancer. <i>Clinical Proteomics</i> , 2011, 8, 11.	2.1	85
65	Reproducibility of residual cancer burden for prognostic assessment of breast cancer after neoadjuvant chemotherapy. <i>Modern Pathology</i> , 2015, 28, 913-920.	5.5	79
66	Randomized Phase III Postoperative Trial of Platinum-Based Chemotherapy Versus Capecitabine in Patients With Residual Triple-Negative Breast Cancer Following Neoadjuvant Chemotherapy: ECOG-ACRIN EA1131. <i>Journal of Clinical Oncology</i> , 2021, 39, 2539-2551.	1.6	78
67	DNA Repair Gene Patterns as Prognostic and Predictive Factors in Molecular Breast Cancer Subtypes. <i>Oncologist</i> , 2013, 18, 1063-1073.	3.7	75
68	Predictors of Chemosensitivity in Triple Negative Breast Cancer: An Integrated Genomic Analysis. <i>PLoS Medicine</i> , 2016, 13, e1002193.	8.4	75
69	Prospective Comparison of Clinical and Genomic Multivariate Predictors of Response to Neoadjuvant Chemotherapy in Breast Cancer. <i>Clinical Cancer Research</i> , 2010, 16, 711-718.	7.0	72
70	MK-2206 and Standard Neoadjuvant Chemotherapy Improves Response in Patients With Human Epidermal Growth Factor Receptor 2-Positive and/or Hormone Receptor-Negative Breast Cancers in the I-SPY 2 Trial. <i>Journal of Clinical Oncology</i> , 2020, 38, 1059-1069.	1.6	69
71	Correlation between HER-2 expression and response to neoadjuvant chemotherapy with 5-fluorouracil, doxorubicin, and cyclophosphamide in patients with breast carcinoma. <i>Cancer</i> , 2003, 97, 1758-1765.	4.1	65
72	Gene Expression, Molecular Class Changes, and Pathway Analysis after Neoadjuvant Systemic Therapy for Breast Cancer. <i>Clinical Cancer Research</i> , 2012, 18, 1109-1119.	7.0	62

#	ARTICLE	IF	CITATIONS
73	Tumor Biology and Response to Chemotherapy Impact Breast Cancer-specific Survival in Node-positive Breast Cancer Patients Treated With Neoadjuvant Chemotherapy. <i>Annals of Surgery</i> , 2017, 266, 667-676.	4.2	62
74	Biologic and immunologic effects of preoperative trastuzumab for ductal carcinoma in situ of the breast. <i>Cancer</i> , 2011, 117, 39-47.	4.1	59
75	Evaluation of biological pathways involved in chemotherapy response in breast cancer. <i>Breast Cancer Research</i> , 2008, 10, R37.	5.0	53
76	Malignant melanoma metastatic to the breast. , 1998, 84, 160-162.		51
77	Clinical evaluation of chemotherapy response predictors developed from breast cancer cell lines. <i>Breast Cancer Research and Treatment</i> , 2010, 121, 301-309.	2.5	50
78	PIK3CA-activating mutations and chemotherapy sensitivity in stage IIâ€“III breast cancer. <i>Breast Cancer Research</i> , 2008, 10, R27.	5.0	49
79	Relationship between Complete Pathologic Response to Neoadjuvant Chemotherapy and Survival in Triple-Negative Breast Cancer. <i>Clinical Cancer Research</i> , 2016, 22, 26-33.	7.0	49
80	SETER/PR: a robust 18-gene predictor for sensitivity to endocrine therapy for metastatic breast cancer. <i>Npj Breast Cancer</i> , 2019, 5, 16.	5.2	48
81	Influence of Biospecimen Variables on Proteomic Biomarkers in Breast Cancer. <i>Clinical Cancer Research</i> , 2014, 20, 3870-3883.	7.0	47
82	Cytoplasmic Cyclin E Predicts Recurrence in Patients with Breast Cancer. <i>Clinical Cancer Research</i> , 2017, 23, 2991-3002.	7.0	46
83	Comparison of the Predictive Accuracy of DNA Array-Based Multigene Classifiers across cDNA Arrays and Affymetrix GeneChips. <i>Journal of Molecular Diagnostics</i> , 2005, 7, 357-367.	2.8	44
84	Proliferation and estrogen signaling can distinguish patients at risk for early versus late relapse among estrogen receptor positive breast cancers. <i>Breast Cancer Research</i> , 2013, 15, R86.	5.0	44
85	Assessment of Residual Cancer Burden and Event-Free Survival in Neoadjuvant Treatment for High-risk Breast Cancer. <i>JAMA Oncology</i> , 2021, 7, 1654.	7.1	42
86	A single-gene biomarker identifies breast cancers associated with immature cell type and short duration of prior breastfeeding. <i>Endocrine-Related Cancer</i> , 2005, 12, 1059-1069.	3.1	38
87	Transfectedneu oncogene induces human prostate cancer metastasis. , 1996, 28, 73-83.		37
88	Association of Immunophenotype With Pathologic Complete Response to Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer. <i>JAMA Oncology</i> , 2021, 7, 603.	7.1	37
89	First generation prognostic gene signatures for breast cancer predict both survival and chemotherapy sensitivity and identify overlapping patient populations. <i>Breast Cancer Research and Treatment</i> , 2011, 130, 155-164.	2.5	36
90	Neoadjuvant T-DM1/pertuzumab and paclitaxel/trastuzumab/pertuzumab for HER2+ breast cancer in the adaptively randomized I-SPY2 trial. <i>Nature Communications</i> , 2021, 12, 6428.	12.8	36

#	ARTICLE	IF	CITATIONS
91	Accurate RNA Sequencing From Formalin-Fixed Cancer Tissue to Represent High-Quality Transcriptome From Frozen Tissue. <i>JCO Precision Oncology</i> , 2018, 2018, 1-9.	3.0	35
92	The incidence of positive margins with breast conserving therapy following mammotome biopsy for microcalcification. <i>Journal of Surgical Oncology</i> , 2000, 74, 263-266.	1.7	33
93	MicroRNA expression profiling identifies decreased expression of miR-205 in inflammatory breast cancer. <i>Modern Pathology</i> , 2016, 29, 330-346.	5.5	33
94	Reproducibility of Gene Expression Signature-Based Predictions in Replicate Experiments. <i>Clinical Cancer Research</i> , 2006, 12, 1721-1727.	7.0	32
95	A functional genomic screen in vivo identifies CEACAM5 as a clinically relevant driver of breast cancer metastasis. <i>Npj Breast Cancer</i> , 2018, 4, 9.	5.2	32
96	A prospective comparison of stereotaxic fine-needle aspiration versus stereotaxic core needle biopsy for the diagnosis of mammographic abnormalities. , 1999, 85, 1119-1132.		31
97	Aspiration biopsy and the clinical management of patients with malignant melanoma and palpable regional lymph nodes. <i>Cancer</i> , 2000, 90, 162-166.	4.1	31
98	The impact of RNA extraction method on accurate RNA sequencing from formalin-fixed paraffin-embedded tissues. <i>BMC Cancer</i> , 2019, 19, 1189.	2.6	30
99	Global gene expression changes induced by prolonged cold ischemic stress and preservation method of breast cancer tissue. <i>Molecular Oncology</i> , 2014, 8, 717-727.	4.6	29
100	Immune Phenotype and Response to Neoadjuvant Therapy in Triple-Negative Breast Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 5365-5375.	7.0	29
101	Development of Candidate Genomic Markers to Select Breast Cancer Patients for Dasatinib Therapy. <i>Molecular Cancer Therapeutics</i> , 2010, 9, 1120-1127.	4.1	28
102	Neoadjuvant Doxorubicin/Cyclophosphamide Followed by Ixabepilone or Paclitaxel in Early Stage Breast Cancer and Evaluation of $\beta$ -Tubulin Expression as a Predictive Marker. <i>Oncologist</i> , 2013, 18, 787-794.	3.7	28
103	Gene Signature-Guided Dasatinib Therapy in Metastatic Breast Cancer. <i>Clinical Cancer Research</i> , 2014, 20, 5265-5271.	7.0	28
104	NF1 inactivation cooperates with N-Ras in in vivo lymphogenesis activating Erk by a mechanism independent of its Ras-GTPase accelerating activity. <i>Oncogene</i> , 1998, 17, 1705-1716.	5.9	26
105	Thirty-Gene Pharmacogenomic Test Correlates with Residual Cancer Burden after Preoperative Chemotherapy for Breast Cancer. <i>Clinical Cancer Research</i> , 2007, 13, 4078-4082.	7.0	26
106	Surgical Standards for Management of the Axilla in Breast Cancer Clinical Trials with Pathological Complete Response Endpoint. <i>Npj Breast Cancer</i> , 2018, 4, 26.	5.2	24
107	Increased Yield of Total RNA from Fine-Needle Aspirates for Use in Expression Microarray Analysis. <i>BioTechniques</i> , 2002, 33, 890-896.	1.8	22
108	Standardizing of Pathology in Patients Receiving Neoadjuvant Chemotherapy. <i>Annals of Surgical Oncology</i> , 2016, 23, 3153-3161.	1.5	22

#	ARTICLE	IF	CITATIONS
109	Hormonal modulation of ESR1 mutant metastasis. <i>Oncogene</i> , 2021, 40, 997-1011.	5.9	22
110	Performance of Mid-Treatment Breast Ultrasound and Axillary Ultrasound in Predicting Response to Neoadjuvant Chemotherapy by Breast Cancer Subtype. <i>Oncologist</i> , 2017, 22, 394-401.	3.7	21
111	Human leucocyte antigen class I in hormone receptor-positive, HER2-negative breast cancer: association with response and survival after neoadjuvant chemotherapy. <i>Breast Cancer Research</i> , 2019, 21, 142.	5.0	21
112	Predicted sensitivity to endocrine therapy for stage II-III hormone receptor-positive and HER2-negative (HR+/HER2 <sup>-</sup> ) breast cancer before chemo-endocrine therapy. <i>Annals of Oncology</i> , 2021, 32, 642-651.	1.2	21
113	Invasive carcinoma in clinically suspicious breast masses diagnosed as adenocarcinoma by fine-needle aspiration. , 2000, 90, 96-101.		20
114	Decreased expression of microRNA-26b in locally advanced and inflammatory breast cancer. <i>Human Pathology</i> , 2018, 77, 121-129.	2.0	20
115	A phase II study of Mirvetuximab Soravtansine in triple-negative breast cancer. <i>Investigational New Drugs</i> , 2021, 39, 509-515.	2.6	18
116	Pancreatic Endocrine Tumor with Signet Ring Cell Features: A Case Report with Novel Ultrastructural Observations. <i>Ultrastructural Pathology</i> , 1998, 22, 147-152.	0.9	17
117	Use of E-cadherin and CD44 aids in the differentiation between reactive mesothelial cells and carcinoma cells in pelvic washings. <i>Cancer</i> , 2000, 90, 299-306.	4.1	17
118	Proposals for uniform collection of biospecimens from neoadjuvant breast cancer clinical trials: timing and specimen types. <i>Lancet Oncology</i> , The, 2011, 12, 1162-1168.	10.7	17
119	Individualized chemotherapy treatment for breast cancer: is it necessary? Is it feasible?. <i>Drug Resistance Updates</i> , 2004, 7, 325-331.	14.4	16
120	Application of a risk-management framework for integration of stromal tumor-infiltrating lymphocytes in clinical trials. <i>Npj Breast Cancer</i> , 2020, 6, 15.	5.2	16
121	Mammary stem cell and macrophage markers are enriched in normal tissue adjacent to inflammatory breast cancer. <i>Breast Cancer Research and Treatment</i> , 2018, 171, 283-293.	2.5	15
122	Reproducibility of Variant Calls in Replicate Next Generation Sequencing Experiments. <i>PLoS ONE</i> , 2015, 10, e0119230.	2.5	14
123	Imaging features of triple-negative breast cancers according to androgen receptor status. <i>European Journal of Radiology</i> , 2019, 114, 167-174.	2.6	14
124	Ganitumab and metformin plus standard neoadjuvant therapy in stage 2/3 breast cancer. <i>Npj Breast Cancer</i> , 2021, 7, 131.	5.2	13
125	Matched cohort study of germline BRCA mutation carriers with triple negative breast cancer in brightness. <i>Npj Breast Cancer</i> , 2021, 7, 142.	5.2	13
126	Stereotaxic aspiration biopsy in the evaluation of mammographically detected clustered microcalcification. , 1998, 84, 226-230.		9



#	ARTICLE	IF	CITATIONS
127	What is the role of cytopathologists in stereotaxic needle biopsy diagnosis of nonpalpable mammographic abnormalities?. <i>Diagnostic Cytopathology</i> , 2001, 24, 260-270.	1.0	9
128	A Pathologist's Perspective on Emerging Genomic Tests for Breast Cancer. <i>Seminars in Oncology</i> , 2007, 34, S4-S9.	2.2	9
129	Bone metastasis-related signaling pathways in breast cancers stratified by estrogen receptor status. <i>Journal of Cancer</i> , 2017, 8, 1045-1052.	2.5	9
130	Pharmacologic profiling of patient-derived xenograft models of primary treatment-naïve triple-negative breast cancer. <i>Scientific Reports</i> , 2020, 10, 17899.	3.3	9
131	RefSeq Refinements of UniGene-Based Gene Matching Improve the Correlation of Expression Measurements Between Two Microarray Platforms. <i>Applied Bioinformatics</i> , 2006, 5, 89-98.	1.6	8
132	Alliance A011801 (compassHER2 RD): postneoadjuvant T-DM1+ tucatinib/placebo in patients with residual HER2-positive invasive breast cancer. <i>Future Oncology</i> , 2021, 17, 4665-4676.	2.4	8
133	A 3-gene proliferation score (TOP-FOX-67) can re-classify histological grade-2, ER-positive breast cancers into low- and high-risk prognostic categories. <i>Breast Cancer Research and Treatment</i> , 2013, 138, 691-698.	2.5	6
134	Targeted RNAseq assay incorporating unique molecular identifiers for improved quantification of gene expression signatures and transcribed mutation fraction in fixed tumor samples. <i>BMC Cancer</i> , 2021, 21, 114.	2.6	6
135	A randomized, triple negative breast cancer enrolling trial to confirm molecular profiling improves survival (ARTEMIS).. <i>Journal of Clinical Oncology</i> , 2017, 35, TPS590-TPS590.	1.6	6
136	Evaluation of Sensitivity to Endocrine Therapy Index (SET2,3) for Response to Neoadjuvant Endocrine Therapy and Longer-Term Breast Cancer Patient Outcomes (Alliance Z1031). <i>Clinical Cancer Research</i> , 2022, 28, 3287-3295.	7.0	6
137	Epithelial Displacement. <i>American Journal of Surgical Pathology</i> , 1995, 19, 1092.	3.7	5
138	Novel Functional Assay for Spindle-Assembly Checkpoint by Cyclin-Dependent Kinase Activity to Predict Taxane Chemosensitivity in Breast Tumor Patient. <i>Journal of Cancer</i> , 2013, 4, 697-702.	2.5	5
139	CCR 20th Anniversary Commentary: Divide and Conquer—Breast Cancer Subtypes and Response to Therapy. <i>Clinical Cancer Research</i> , 2015, 21, 3575-3577.	7.0	5
140	Technical Validity of a Customized Assay of Sensitivity to Endocrine Therapy Using Sections from Fixed Breast Cancer Tissue. <i>Clinical Chemistry</i> , 2020, 66, 934-945.	3.2	5
141	Radial Sclerosing Lesion: Correlation Between Mammotome Core Biopsy and Surgical Excision. <i>Breast Journal</i> , 2001, 7, 66-67.	1.0	4
142	Genomic Testing for Sensitivity of Breast Cancer to Hormonal Therapy. <i>Clinical Cancer Research</i> , 2006, 12, 1954-1955.	7.0	4
143	Gene-expression microarrays provide new prognostic and predictive tests for breast cancer. <i>Pharmacogenomics</i> , 2007, 8, 1359-1368.	1.3	4
144	Uncertainty estimation with a finite dataset in the assessment of classification models. <i>Computational Statistics and Data Analysis</i> , 2012, 56, 1016-1027.	1.2	4

#	ARTICLE	IF	CITATIONS
145	Genomic predictor of residual risk of recurrence after adjuvant chemotherapy and endocrine therapy in high risk estrogen receptor-positive breast cancers. <i>Breast Cancer Research and Treatment</i> , 2015, 149, 789-797.	2.5	4
146	Axillary ultrasound during neoadjuvant systemic therapy in triple-negative breast cancer patients. <i>European Journal of Radiology</i> , 2020, 130, 109170.	2.6	4
147	Prognostic Impact of High Baseline Stromal Tumor-Infiltrating Lymphocytes in the Absence of Pathologic Complete Response in Early-Stage Triple-Negative Breast Cancer. <i>Cancers</i> , 2022, 14, 1323.	3.7	4
148	Intra- and Interlaboratory Reproducibility of the Sensitivity to Endocrine Therapy Assay for Stage II/III Breast Cancer. <i>Clinical Chemistry</i> , 2021, 67, 1240-1248.	3.2	3
149	Reply to T. Shimoi et al and Y. Shimanuki et al. <i>Journal of Clinical Oncology</i> , 2021, 39, JCO.21.01905.	1.6	3
150	Interpreting the Complex Landscape of Immune-Tumor Interface. <i>Clinical Cancer Research</i> , 2021, 27, 5446-5448.	7.0	2
151	Personalized medicine for breast cancer: moving forward and going back. <i>Personalized Medicine</i> , 2006, 3, 363-370.	1.5	1
152	Breast Cancer Genomics: Challenges in Interpretation and Application. <i>Oncologist</i> , 2013, 18, e11-2.	3.7	1
153	Breast Cancer Prognostic and Predictive Factors. <i>Seminars in Breast Disease</i> , 2004, 7, 91-100.	0.0	0
154	Molecular Pathology Assays for Breast Cancer. , 2005, , 145-168.		0
155	Pathology After Neoadjuvant Treatments. , 2017, , 141-147.		0
156	A perspective on genomic tests for breast cancer: the need for progress. <i>Oncology</i> , 2012, 26, 364-5, 369.	0.5	0
157	Survivorship after neoadjuvant chemotherapy – Authors' reply. <i>Lancet Oncology</i> , The, 2022, 23, e96.	10.7	0
158	Challenges and Gaps in Clinical Trial Genomic Data Management. <i>JCO Clinical Cancer Informatics</i> , 2022, 6, e2100193.	2.1	0